Passage Bio has stopped enrolling patients into upliFT-D, the phase 1/2 trial of PBFT02 and the longest running gene therapy programme in frontotemporal dementia caused by mutations in the GRN gene (FTD-GRN). In a filing with the United States Securities and Exchange Commission on 20 April 2026, the company reported updated interim results from the trial and said that at a recent Type C meeting the Food and Drug Administration had not supported a single-arm design and had indicated that a randomised controlled trial would be required for registrational purposes. The Association for Frontotemporal Degeneration reported on 15 May 2026 that the company had told the FTD community it was discontinuing the trial and would not take new patients. The regulator has published nothing of its own on the matter; the FDA's position is known only through the sponsor's disclosure.
upliFT-D (registered as NCT04747431) is an open-label, single-arm, multi-centre study of PBFT02, an AAV1 vector carrying a copy of the human GRN gene, given once by injection into the cisterna magna. The interim data reported on 20 April, current to 23 March 2026 and covering 10 FTD-GRN patients and one FTD-C9orf72 patient, are preliminary and uncontrolled. Among the two treated patients who entered the trial at a global Clinical Dementia Rating of 1, whole brain atrophy at 12 months averaged 3.1 percent against 9.9 percent in a sample of seven untreated CDR 1 patients drawn from the ALLFTD natural history dataset, with frontotemporal cortex atrophy of 4.6 percent against a natural history figure the company put higher; patients who entered at CDR 2 showed no improvement on either measure. Plasma neurofilament light fell by an average of 1.0 pg/mL at 12 months in six treated patients, against an average rise of 13.5 pg/mL in seven untreated patients from the same dataset. A peer-reviewed interim report from the trial, published in Alzheimer's and Dementia on 25 December 2025 and covering the first seven participants dosed as of December 2024, recorded cerebrospinal fluid progranulin rising from below 3 ng/mL at baseline to 13 to 27 ng/mL at six months in four participants, and three treatment-related serious adverse events in two participants: two episodes of asymptomatic venous sinus thrombosis and one of hepatotoxicity.
The corporate consequences followed quickly. In an 8-K filed on 28 April 2026, Passage Bio disclosed a restructuring plan cutting its workforce by approximately 75 percent, with severance and exit costs of about 3.3 million dollars. On 23 June 2026 the company gave the University of Pennsylvania notice terminating its licence rights to develop or commercialise PBFT02, effective 90 days after receipt, and terminated its manufacturing agreement with Catalent. A registration statement filed with the SEC on 21 July 2026 describes the wind-down of the gene therapy programmes and an all-stock merger with Remix Therapeutics, put to shareholders and expected to close in the fourth quarter of 2026.
The evidentiary argument cuts both ways. The company said the atrophy and neurofilament comparisons rested on robust natural history data in a rare and underserved disease; those comparisons involved two to six treated patients matched against external, untreated samples, not a randomised control group, and imaging and blood markers are not the same as a measured change in how a person functions. The Association for Frontotemporal Degeneration noted that a placebo-controlled design in this setting means sham surgery under anaesthesia, with no prospect of benefit for those assigned to it. Families with a relative already dosed in upliFT-D, and clinicians running the sites, should direct questions about continued follow-up to their trial site rather than to any public statement.